spacer
home > ict > spring 2020 > is the pandemic a time for inflection or reflection?
PUBLICATIONS
International Clinical Trials

Is the Pandemic a Time for Inflection or Reflection?



Right now, it may feel as though clinical research on anything other than COVID-19 has ground to a halt. Of course, our incredible scientists should be racing to launch vaccine and treatment trials – the whole world wishes them well – but for some patients and families, the delays to the trials that affect their own personal treatment odyssey are nothing short of heartbreaking.

Whether organisations choose to delay or forge ahead with their planned trials in these unprecedented times, there is a great deal of support for them. In the US, the FDA has issued guidance for trials that might have to pause their studies, and the world’s ethics committees are offering advice to all those submitting requests to alter trial plans. Some of those organisations that fund clinical trials have also shown amazing flexibility, with the US National Cancer Institute announcing that it will, if possible, allow its investigators to assess trial participants’ health remotely.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Sarah Beeby, Executive Vice President, General Manager Life Sciences, at Clinithink has over two decades of experience in the global life science industry and has a wide range of operational, therapeutic, and regulatory expertise, with a focus on collaborative working opportunities to enhance delivery and patient experience. Her diverse background in life sciences, in roles ranging from Clinical Research Associate, Global Program Manager, and Vice President to Chief Operating Officer in pharmaceutical, CRO, medical device, and investigator site companies, has made her a globally recognised leader in the industry. Sarah joined Clinithink in 2017 to bring technology, in particular artificial intelligence, to life science projects. Sarah has a particular interest in the opportunities and business changes that accompany disruptive technology, as well as the potential outcomes of delivering clinical trials and novel treatments to wider patient populations.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mural Health Enters the Market to Disrupt Clinical Trial Participant Management Through the Launch of Mural Link Platform

Founders Respond to Participant Needs to Drive Trial Retention
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement